Table 3.
GSE36765. The pathway activity in TIL CD4+ T cells related to the additional clinical information which was described before [19]. Signaling pathway activity scores are presented as log2 odds with color coding ranging from blue (most inactive) to red (most active). The TGFβ and NFκB pathway activities were significantly lower in triple-negative patients compared to in the other subtypes (p = 0.028 and p = 0.028, respectively).
| Annotation per Sample | FOXO | NFκB | JAK-STAT1/2 | JAK-STAT3 | TGFβ | Notch | Age | ER a | PR b | HER2 c | Tumor Size (cm) d | LN Metastasis e | T cell Infiltrate f | Histological Grade g |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIL pt 3 | 10.9 | 30.3 | −1.2 | 0.9 | −2.4 | 9.3 | 43 | + | + | − | 2.8 | 0/12 | minimal | 3 (SBR8) |
| TIL pt 1 | 5.6 | 21.5 | −6.3 | −3.9 | −7.5 | 6.3 | 51 | + | + | − | 1.8 | 0/16 | minimal | 2 (SBR6) |
| TIL pt 5 | 7.2 | 31.3 | −4.0 | 5.4 | −4.8 | 7.0 | 58 | + | + | − | 4 | 1/10 | minimal | 2 (SBR7) |
| TIL pt 2 | 6.9 | 26.8 | 0.5 | 1.2 | −6.8 | 2.5 | 56 | + | + | − | 1.8 | 1/19 | extensive | 2 (SBR7) |
| TIL pt 4 | 0.9 | 23.5 | 0.9 | 0.3 | −8.5 | 1.5 | 42 | + | + | + | 4.4 | 7/26 | extensive | 3 (SBR9) |
| TIL pt 10 | 14.5 | 24.8 | −2.2 | 1.3 | −7.4 | 9.3 | 61 | − | − | − | 3.5 | 0/11 | extensive | 3 (SBR9) |
| TIL pt 7 | 5.4 | 22.8 | −1.3 | 0.4 | −9.0 | 5.6 | 54 | − | − | − | 1.8 | 0/13 | extensive | 3 (SBR9) |
| TIL pt 6 | 9.6 | 19.0 | −9.8 | −3.3 | −10.4 | 4.0 | 74 | − | − | − | 0.4 M | 0/14 | minimal | 3 (SBR8) |
| TIL pt 8 | 3.2 | 13.6 | −4.5 | −3.2 | −8.3 | 5.2 | 68 | − | − | − | 2.7 | 0/20 | minimal | 3 (SBR8) |
| TIL pt 9 | −1.9 | 18.1 | −3.4 | −4.2 | −14.2 | −1.3 | 82 | − | − | − | 2.5 M | 20/22 | minimal | 3 (SBR8) |
|
a Estrogen receptor 1 (ESR1); estrogen receptor alpha b Progesterone receptor. c CD340, HER-2/neu, ERBB2. d For multi-focal tumors, the size of the largest invasive foci is indicated followed by M for multifocal. e The number of positive LNs/number of examined LNs. f The extent of T cell infiltrate determined by immunohistochemistry (IHC; CD3 and CD4 labeling) g Scarff Bloom-Richardson staging score Breast cancer subtypes are color coded according to IHC staining: | ||||||||||||||
| ER+ HER2− | HER2+ | ER− HER2− | ||||||||||||